Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.

Cardiol Clin

Department of Internal Medicine, University of Cincinnati Medical Center, University of Cincinnati, 51 Goodman Drive, Cincinnati, OH 45267, USA; University of Cincinnati, VAMC Cincinnati, 3200 Vine Street, Cincinnati, OH 45267, USA. Electronic address:

Published: August 2019

Diabetes is a major risk factor for cardiovascular disease, yet until now treatments for diabetes had only a modest impact on cardiovascular events. New interventions for patients with type 2 diabetes mellitus (oral empagliflozin and injectable liraglutide) are associated with unprecedented reductions in composite cardiovascular outcomes that seem disproportionate to the impact on glycated hemoglobin. This review examines in detail the recent trials that arrived at these conclusions, limitations of these studies, and how these outcomes may influence patient management in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccl.2019.04.007DOI Listing

Publication Analysis

Top Keywords

novel antidiabetic
4
antidiabetic therapies
4
cardiovascular
4
therapies cardiovascular
4
cardiovascular risk
4
risk reduction
4
reduction role
4
role noninferiority
4
noninferiority trial
4
trial diabetes
4

Similar Publications

The discovery of novel counteractive pharmaceuticals, which have recently generated much interest, has played a significant role in the development of drugs derived from herbal medicines or botanical sources. Paederia foetida (P. foetida) is one such example of a role in both traditional and traditional medicine.

View Article and Find Full Text PDF

Ischemia reperfusion-induced myocardial injury is a prominent pathological feature in patients with coronary artery disease, contributing to significant mortality and morbidity rates. Mangiferin (MGF), the main active ingredient extracted from Anemarrhena asphodeloides Bge, has anti-inflammatory, anti-oxidation, anti-diabetes, and anti-tumor effects. The present study confirmed that the GAS6/Axl pathway was identified as a promising novel target for the treatment of myocardial ischemia reperfusion (IR) injury.

View Article and Find Full Text PDF

Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes.

View Article and Find Full Text PDF

Computational insights into marine natural products as potential antidiabetic agents targeting the SIK2 protein kinase domain.

SAR QSAR Environ Res

December 2024

Structural Biology and Biocomputing Lab, Department of Bioinformatics, Alagappa University, Karaikudi, India.

Diabetes mellitus (DM) affects over 77 million adults in India, with cases expected to reach 134 million by 2045. Current treatments, including sulfonylureas and thiazolidinediones, are inadequate, underscoring the need for novel therapeutic strategies. This study investigates marine natural products (MNPs) as alternative therapeutic agents targeting SIK2, a key enzyme involved in DM.

View Article and Find Full Text PDF

Linn ( L.), commonly known as Holy Basil or Tulsi, is a fragrant herbaceous plant belonging to the Lamiaceae family. This plant is widely cultivated and found in north-central parts of India, several Arab countries, West Africa and tropical regions of the Eastern World.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!